What is the recommended Svetinorm dosage?

Svetinorm dosing varies by experience level. Beginners typically start at 10mg daily, moderate users at 10mg 2x daily, and aggressive protocols use 20mg 2x daily.

How do you reconstitute Svetinorm?

Svetinorm comes as a pre-filled device — no reconstitution needed.

What is the half-life of Svetinorm?

The half-life of Svetinorm is ~0.5-1 hour (estimated from tetrapeptide class). This determines how frequently you need to dose for consistent blood levels.

Svetinorm

MetabolicOralResearchGrade C~0.5-1 hour (estimated from tetrapeptide class) half-life

BioregulatorLiverHepatoprotectiveKhavinson PeptideTetrapeptide4 weeks on / 16 weeks off

Benefits

May support liver protein synthesis and hepatocyte renewal (preclinical data)

Stabilization of ALT and bilirubin observed in a small clinical study

Proposed reduction in inflammatory markers (IgM) during liver disease

Supports phase I and phase II liver detoxification enzyme expression (in vitro)

Potential antioxidant and immunoprotective effects in aging liver tissue

Half-Life

~0.5-1 hour

Route

Oral

Frequency

Daily

Vial Sizes

20mg, 60mg

BAC Water

Pre-filled

Safety Grade

Grade C

Open Svetinorm Dosage Calculator

Calculate exact syringe units for your vial and dose

About Svetinorm

Svetinorm is an oral peptide bioregulator developed by Prof. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology. It contains peptide complex A-7 — a mixture of low-molecular-weight peptides (under 10 kDa) extracted from the liver tissue of young calves. The active component is believed to include or relate to the tetrapeptide KEDA (Lys-Glu-Asp-Ala), also known as Livagen, which has shown tissue-specific affinity for hepatocytes in preclinical studies. Svetinorm is designed to restore protein synthesis in aging or damaged liver cells by interacting with DNA promoter regions and activating gene transcription. A small clinical study at Khavinson's institute (2003-2004) enrolled patients with chronic hepatitis and post-chemotherapy liver damage. Those receiving Svetinorm alongside standard treatment showed stabilized ALT (alanine aminotransferase) and bilirubin levels, along with decreased IgM — a marker of inflammatory activity. The researchers concluded it had hepatoprotective properties suitable for chronic liver disorders and post-radiation recovery. However, the evidence base is narrow: most data comes from a single Russian research group, no randomized controlled trials have been published in Western journals, and the exact peptide composition of A-7 isn't publicly disclosed. Users should consider Svetinorm an experimental bioregulator with promising but unconfirmed hepatoprotective potential.

Who Should Consider Svetinorm

Adults over 40 with age-related liver function decline
Individuals recovering from chemotherapy or radiation therapy
Those with chronic hepatitis seeking adjunctive support (under medical supervision)
Health-optimizers interested in liver detoxification support
Researchers studying Khavinson bioregulator peptides

How Svetinorm Works

Svetinorm delivers short peptides that exhibit tissue-specific affinity for hepatocytes. The key tetrapeptide KEDA (Lys-Glu-Asp-Ala) penetrates cell nuclei and interacts with DNA promoter regions through complementary binding, causing local unwinding of the double helix and activating RNA polymerase-driven transcription. In aged liver cells, this results in heterochromatin decondensation at ribosomal gene loci on chromosomes 1, 9, and 16 — essentially reactivating genes that had been silenced by age-related chromatin compaction. Downstream effects include upregulation of CYP450 phase I detoxification enzymes, glutathione S-transferase (GST) and UDP-glucuronosyltransferase (UGT) for phase II conjugation, and increased albumin synthesis. KEDA also modulates hepatocyte growth factor (HGF) receptor expression, supporting liver regeneration after injury. In organotypic liver cultures from old rats, KEDA restored protein synthesis rates to levels comparable to young tissue.

What to Expect

Days 1-7

No noticeable external changes expected. Peptide-DNA interactions begin at the cellular level. Gene transcription changes are accumulating in hepatocytes but won't be perceptible.

Weeks 2-3

Some users anecdotally report improved energy and digestion. In the clinical study, biochemical markers (ALT, bilirubin) began stabilizing during this phase. Effects are subtle and difficult to distinguish from placebo.

Week 4

end of course

End of standard on-cycle. The clinical study showed measurable stabilization of liver enzymes and decreased IgM levels by this point. Improvements in liver function tests may be confirmable via bloodwork.

Months 2-6

off-cycle

Bioregulator theory holds that epigenetic changes persist after discontinuation. Liver enzyme levels should remain stable. Plan the next course for 4-6 months later.

Dosing Protocol

Level	Dose / Injection	Frequency
Beginner	10mg	Daily
Moderate	10mg	2x Daily
Aggressive	20mg	2x Daily

Note: Khavinson liver peptide bioregulator containing peptide complex A-7 extracted from young animal liver tissue. Oral capsules — no reconstitution needed. Standard course is 1-2 capsules, 1-2 times daily with meals for 20-30 days. Repeat 2-3 times per year. Very limited Western clinical data.

How to Inject Svetinorm

Take 1-2 capsules with meals, 1-2 times daily. Swallow whole with water. No reconstitution or injection required. Best taken with food to support absorption. A standard course lasts 20-30 days.

Cycling Protocol

On Period

4 weeks

Off Period

16 weeks

Standard Khavinson bioregulator protocol: 20-30 days on, then off for 4-6 months. Repeat 2-3 times per year. The long off-period allows endogenous regulatory mechanisms to stabilize. Limited data on optimal cycling duration.

Pharmacokinetics

Half-Life

30min

Bioavailability

Oral: not formally characterized; likely low but proposed active at epigenetic-level doses

Tmax

Unknown — no formal PK study published

Data Confidence

low

Source: Estimated from tetrapeptide class pharmacokinetics. No direct PK study exists for Svetinorm or KEDA. Short peptides (2-4 amino acids) are rapidly degraded by peptidases within minutes to an hour.

Pharmacokinetics — Active Dose Over Time

Loading the interactive decay curve.

Side Effects

Generally reported as well-tolerated in limited studies. No serious adverse events documented in the available clinical literature. The safety dataset is very small and comes primarily from uncontrolled Russian studies, so the true side-effect profile isn't well characterized.

Contraindications

Pregnancy or breastfeeding (no safety data available)
Known allergy to animal-derived peptide products
Active liver failure or decompensated cirrhosis (insufficient data for severe disease)
Children under 14 (not studied in pediatric populations)
Organ transplant recipients on immunosuppressants (theoretical interaction concern)

Drug Interactions

Immunosuppressants — Svetinorm may modulate immune markers; monitor if on cyclosporine, tacrolimus, or similar agents
Hepatotoxic medications — theoretical additive liver stress if combined with known hepatotoxins; monitor liver enzymes
Anticoagulants — KEDA peptide has shown effects on blood clotting and fibrinolysis in preclinical models; use caution with warfarin or heparin
No formal drug interaction studies have been conducted